Enhance your ability to manage obesity in cardiovascular patients with up-to-date guidance on FDA-approved pharmacological interventions. Through a focused discussion on pathophysiology, medication impact, and ethical considerations, this course empowers you to make informed, patient-centered decisions in a rapidly evolving therapeutic landscape.
Learning Objectives
- Review the epidemiology and pathophysiology of obesity including the neurohormonal pathways that cause weight gain and prevent sustained weight loss.
- Discuss the pharmacology and indications for the FDA approved anti obesity medications (AOMs) including GLP1-RA’s, along with cardiac considerations of each.
- Review other common obesity-inducing medications specific to the CV patient and considerations for combating these effects.
- Discuss ethical considerations for prescribing AOM’s with the current environment surrounding these medications
CE certificate available upon successful completion of the post-test and program evaluation.

MSN, NP, FAHA, FPCNA

DNP, ARNP, FNP-BC, FPCNA
Chiadi Ndumele
MD, PhD
Accreditation:
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.
Related Resources
Sorry, we couldn't find any resources.
Related Courses
Risk Assessment on the Horizon: Understanding Genetic Lipid abnormalities, screening, and treatments
1.0 CE contact hours
0.75 Pharmacology contact hours
0.75 CE contact hours
0.25 Pharmacology contact hours
Free
0.8 CE contact hours
0.8 Pharmacology contact hours
Free